Pfizer Might Be Cheaper Than You Think

Here's why Pfizer (NYSE: PFE) may be cheaper than you think.

In the daily noise machine of CNBC, analyst estimates, and quarterly announcements, investors are inundated with talking heads obsessing over earnings-per-share figures.

This is the primary metric we use to mark corporate progress. Earnings, or net income, are also the basis for the price-to-earnings ratio, the most popular way of measuring how cheap or expensive a stock is.

Unfortunately, "earnings" figures don't always give you the full picture.

Let me explain
Reported earnings are an accounting construction that may or may not accurately reflect a company's true earnings power. Free cash flow -- the amount of cash a company earns on its operations minus what it spends on them -- is another, oftentimes more accurate metric that can help you identify cheap stocks.

Better still, it's one that other investors frequently overlook. That means investors like us who peek at free cash flow can gain a significant advantage in the market.

How Pfizer stacks up
If Pfizer tends to generate more free cash flow than net income, there's a good chance earnings-per-share figures understate its profitability and overstate its price tag. Conversely, if Pfizer consistently generates less free cash flow than net income, it may be less profitable and more expensive than it appears.

This graph compares Pfizer's historical net income to free cash flow. (I omitted various gains and charges such as tax deferrals, restructurings, and benefits related to stock options.)

Source: Capital IQ, a division of Standard & Poor's, and author's calculations.

As you can see, Pfizer has a tendency to produce more free cash flow than net income.

This means that the standard price-to-earnings multiple investors use to judge companies may overstate its price tag.

Let's examine Pfizer alongside some of its peers for additional context:

Source: Capital IQ and author's calculations. Same adjustments to FCF were used as described above.

Pfizer's free cash flow multiple is considerably less expensive than its earnings multiple, and it's far cheaper than peer free cash flow multiples. As a result, Pfizer may be much cheaper than many investors realize.